Management of chronic hepatitis in drug addicts: A systematic review

Clinica Terapeutica

Volumn 159, Issue 1, 2008, Pages 41-49

  Pellicelli, Adriano M ^a,d   Barbaro, G ^b   Barbarini, G ^c   Soccorsi, F ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d NONE   (Italy)

Author keywords

Chronic viral hepatitis; Drugs addiction; Interferon alpha

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; METHADONE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELBIVUDINE; TENOFOVIR;

CHRONIC HEPATITIS; CLINICAL TRIAL; DELTA AGENT HEPATITIS; DRUG DEPENDENCE; DRUG DOSE COMPARISON; EPIDEMIOLOGICAL DATA; HEPATITIS B; HEPATITIS C; HOST; HUMAN; INFECTION RATE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; PATIENT COMPLIANCE; REVIEW; SEXUAL BEHAVIOR; VIRUS CULTURE; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEPATITIS, CHRONIC; HUMANS; INTERFERON ALFA-2B; ITALY; RIBAVIRIN; ROME; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 40549129365     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Galeazzi B, Tufano A, Barbierato E, et al. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver 1995; 15(4):209-12
2. Quaglio G, Lugoboni F, Pattaro C, et al. Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients. BMC Public Health 2006; 6(1):216
3. Long J, Allwright S, Barry J, et al. Prevalence of antibodies to hepatitis B , hepatitis C and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ 2001; 323(7323):1209-13
4. Chetwynd J, Brunton C, Blank M, et al. Hepatitis C seroprevalence among injection drug users attending a methadone program N Z Med J 1995; 108:364-6
5. Crofts N, Nigro L, Oman K, et al. Methadone mainteinance and hepatitis virus C infectionamong injecting drug users. Addiction 1997; 92:999-1005
6. Chamot E, Hirschel B, Deglon JJ, et al. Incidence of hepatitis C, hepatitis B and HIV infection among drug users in a methadone mainteinance program. AIDS 1992; 6:430-1
7. Selvey LA:, Denton M, Plant AJ. Incidence and prevalence of hepatitis B among clients of a Bisbane methadone clinic: factors influencing hepatitis C serostatus. Aus NZ J Public Health 1997; 21:102-4
8. NovickDM, Joseph H, Croxson TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated metadone mainteinance program. Arch Intern Med 1990; 150:97-9
9. Strain EC, Bigelow GE, Liebson IA, et al. Moderate vs high dose methadone in the treatment of opiod dependence. JAMA 1999; 281:1000-5
10. Thomas DL, Vlahov D, Galai N, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine 1995; 74:212-20
11. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186:1558-64
12. Vitale F, Villafrate MR, Viviano E, et al. Distribution of hepatitis C virus genotypes among intravenous drug users. A ten year study in Palermo, Sicily. New Microbiol 1998; 21:335-42
13. Cournot M, Gilbert A, Castel F, et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004; 28:533-9
14. Backmund M, Meyer C, Von Zielonka M, et al. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-93
15. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factor and genotype distribution of hepatitis C virus infection in the general population: a community based survey in Southern italy. Hepatology 1997; 26:1006-11
16. Hisada M, Chatterrjee N, Kalaylioglu Z, et al. Hepatitis C virus load and survival among injectiondrug users in the United States. Hepatology 2005; 42:1261-3
17. Rai R, Wilson LE, Astemborski J, et al. Severity and correlates of liver disease in hepatitis C virus infected injection drug users. Hepatology 2002; 35:1247-55
18. Fischer B, Rehm J, Brissette S, et al. Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities J Urban Health 2005; 82:250-66
19. Stein A, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001; 61:211-5
20. Fischer B, Vasdev S, Haydon E, et al. Willing to undergone Hepatitis C treatment in a sample of injection drug users in Toronto. Presse Med 2005; 34:1209-12
21. Loftis JM, Hauser P. Hepatitis C in patients with psychiatric disease and substance abuse: screening, strategies, and comanagement models of care. Curr Hepatitis Report 2003; 2:93-100
22. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C Mol Psychiatry 2002; 7:942-97
23. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric groups. Hepatology 2003; 37:443-51
24. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-9
25. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug use.Clin Infect Dis 2004; 39:1540-3
26. NIH Consensus statement on management of hepatitis C. NIH Consensus State Sci Statements 2002; 19:1-46
27. Mauss S, Berger F, Goelz J, Jacob B, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-4
28. Backmund M, Meyer K, Von Zielonka M, et al. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-93
29. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-5
30. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001; 94:153-8
31. Van Thiel DH, Anantharaju A, Creech S. Response to treatmentof hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98:2281-8
32. Cournot M, Gilbert A, Castel F, et al. Management of hepatitis C in active drugs users: experience of an addition care hepatology unit. Gastroenterol Clin Biol 2004; 28:533-9
33. Sylvestre D. Treatment of HCV in the methadone patients: comorbid conditions associated with hepatitis C. AASLD 2002; 103-7
34. Raptopoulou M, Lalla T, Sinakos E, et al. Treatment of intravenous drug users with chronici hepatitis C: treatment response, compliance and side effects. J Hepatol 2006; 44(suppl 2):S223
35. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40:S325-S9
36. Robaeys G, Van Vlierberghe H, Mathei C, et al. Compliance and effect of treatment for chronic hepatitis C in intravenous drug user. J Hepatol 2003; 38(suppl 2):165
37. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short term injection drug users: the prevalence of hepatitis C, hepatitis B, human immunodeficiency and human T-lymphotropic viruses. Am J Pub Health 1996; 86:655-61
38. Broers B, Junet C, Bourquin M, et al. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone mainteinace treatment in Geneva between 1988 and 1995. AIDS 1998; 12:2059-66
39. Baklan Z, Gorisek JR, Poljak M, et al. Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor. Wien Klin Wochenschr 2004; 116(suppl 2):5-7
40. Lugoboni F, Migliozzi S, Mezzelani P, et al. Progressive decrease of hepatitis B in a cohort of drug users followed over a period of 15 years: the impact of anti HBV vaccination. Scan J Infect Dis 2004; 36:131-3
41. Centers for Disease Control and Prevention. Hepatitis B vaccination for injection drug users.Pierce County Washington 2000. MMWR Morb Mortal Wlkl Rep 2001; 50:388-99
42. Patti AM, Santi AL, Pompa MG, et al. Viral hepatitis and drugs: a continuing problem. Int J Epidemiol 1993; 22:135-9
43. Chen CJ, Tseng SF, Lu CF, et al. Current seroepidemiology of hepatitis D virus infection among hepatitis B surface antigen carriers of general and high risk population in Taiwan. J Med Virol 1992; 38:97-101
44. Huo TI, Wu JC, Chang AL, et al. Changing seroepidemiology of hepatitis B,C and D virus infections in high risk population. J Med Virol 2004; 72:41-5
45. Manesis EK, Papatheodoridis GV, Sevastianos V, et al. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003; 98:2261-7
46. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alpha-2a, lamivudine and the combination for HBeAg positive chronic hepatitis B. N Engl J Med 2005; 352:2682-95
47. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha 2a (40KDa) and advance in the treatment of hepatitis B e antigen positive chronic hepatitis B J Viral Hepat 2003; 10:298-305
48. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2 alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-17
49. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-63
50. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8
51. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis e antigen-negative/hepatitis B virus DNA positive chronic hepatitis B Lamivudine precore mutant study group. Hepatology 1999; 29:889-96
52. Allen M, Deslauriers M, Andrews C, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamuvidine. Lamuvidine clinical investigation group. Hepatology 1998; 27:1670-7
53. Liaw Y-F, Leung N, Chang T, et al. Effects of extended lamuvidine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamuvidine study group. Gastroenterology 2000; 119:172-80
54. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-7
55. Hadziyannis S, Tassopoulos N, Heathcote E. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-81
56. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66:1153-8
57. Colonno R, Rose R, Levine S, et al. Entecavir two year resistance update: No resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 2005; 42:573A
58. Gish R, Chang T, De Man R, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients. Hepatology 2005; 42:82A
59. Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.Arch Intern Med 2006; 166(1):49-56
60. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330:137-8
61. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30(2):546-9
62. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22(3):227-32
63. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative R-PCR for follow-up. Hepatology 2006; 44:536-9
64. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta. J Hepatol 2006; 44:S188